MTX: a systemic option for refractory nummular eczema in children

  • Knöpfel N & al.
  • Pediatr Dermatol
  • 26 Jun 2018

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A small retrospective study suggests that methotrexate (MTX) is an effective and well-tolerated treatment for children with moderate-to-severe nummular eczema.

Why this matters

  • This study adds to the limited data concerning use of systemic therapy for nummular eczema in children.

Key results

  • Median treatment duration was 12.6 months, and 50% of patients were still undergoing methotrexate treatment at the final review.
  • At final clinical examination (mean, 13.4 months; median, 9.4 months), 35.7% of patients experienced >90% clearance, 46.4% of patients experienced 50%-89% clearance, 14.3% of patients experienced
  • 21.4% of patients experienced gastrointestinal intolerance and 17.9% experienced a nonsignificant increase in liver enzymes.
  • No serious adverse events were documented.

Study design

  • 28 children with nummular eczema were treated with methotrexate and analyzed for efficacy and safety outcomes.
  • Funding: None disclosed.

Limitations

  • Very small patient sample size.
  • Retrospective study design.
  • No control group.
  • Topical corticosteroids were also used during study period.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit